Abstract Body

Background: The emergence of HIV-specific CD8 T cell responses during acute HIV infection has been previously associated with a post peak decline of HIV viremia, resolution of clinical symptoms and the development of a semi-stable viral setpoint; this early viral setpoint has been shown to be highly predictive of disease outcome. Given the importance of early HIV-specific CD8 T cell responses, we assessed which particular HIV-specific CD8 T cell responses contribute to long-term control. Methodology: 622 predominantly male (97%) Caucasian (83%) individuals with primary HIV-1 infection (Fiebig: n= 152 (2/3), 61 (4), 277 (5), 87 (6), 23 (nd)) were screened by IFNγ Elispot for HLA class I-restricted, epitope-specific CD8+ T cell responses using optimally defined epitopes approximately 2 months post initial presentation. Longitudinal viral load, CD4 count and time to HAART were collected of all patients over an average period of 1000 days post presentation. Results: Initial viremia and early viral set points were significantly associated with HLA class I expression (p<0.0001). Similarly, the time patients remained off antiretroviral therapy also showed significant association with HLA class I. In particular, patients with HLA-B57 and -B13 initiated HAART significantly later than individuals expressing HLA-B8 and B7 (p<0.0001). However, no association of HLA with initial CD4 count was found. Interestingly, among the HLA class I alleles, the presence or absence of individual HIV-specific CD8 T cell responses had a significant impact on disease progression. A larger breadth of HIV-specific CD8 T cell responses during primary HIV infection was associated with significantly slower disease progression. Moreover, the induction of certain HIV-specific CD8 T cell responses significantly influenced disease progression, while others had little to no impact. For example, HLA-B27+ individuals that generated an HLA-B27-KK10 response during primary HIV infection had significantly slower disease progression than patients that did not mount this response (p=0.0002). In contrast, CD8 T cell responses against epitopes such as HLA-B8-EI8 (p24) or HLA-B57-HW9 (Nef) did not show any influence on disease progression. Conclusions: Our data demonstrate strong associations of CD8+ T cell responses against specific epitopes with long-term HIV control, while others did not show any association despite being restricted by the same HLA class I allele. Thus, engineered proteins focusing the immune response towards specific epitopes might provide an important approach for vaccine design strategies.